Richard B. Moss

Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.

R. Amin, H. Fuchs, R. Moss, 1996, American journal of respiratory and critical care medicine.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

J. Clancy, M. Ballmann, F. Accurso, 2011, Thorax.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

F. Accurso, M. Ashlock, M. Konstan, 2012 .

Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.

C. Goss, J. Clancy, L. Herzenberg, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Pediatric Pulmonology

D. Cornfield, R. Behrje, M. Yilma, 2020 .

A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.

R. Gibson, T. Reynolds, D. Waltz, 2001, Human gene therapy.

Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.

J. Clancy, D. Waltz, B. Ramsey, 2004, Chest.